LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.

Treatment of advanced prostate cancer with a combination of luteinising hormone-releasing hormone analogues and anti-androgens is advisable for the initial 2 weeks, in patients with newly diagnosed, extensive disease. Advances in long-term combination treatment are questionable until results of phase III studies become available. Reference is made to poster presentations at the International Symposium on Endocrine Therapy.